PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple myeloma |
| Symptom | C0341697|renal impairment |
| Sentences | 23 |
| PubMedID- 25003848 | The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. |
| PubMedID- 23592895 | Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment. |
| PubMedID- 22739170 | Clinical study of bortezomib for treating multiple myeloma with renal impairment. |
| PubMedID- 20479544 | Aims: this retrospective study investigated the rates of renal impairment in patients with multiple myeloma treated with zoledronic acid and ibandronate. |
| PubMedID- 21343553 | renal impairment in multiple myeloma: time is of the essence. |
| PubMedID- 22763386 | The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen. |
| PubMedID- 21973045 | Background: reversal of renal impairment (ri) in patients with multiple myeloma (mm) has been evaluated using the estimated glomerular filtration rate (egfr(mdrd) ) formula developed by the modification of diet in renal disease study group. |
| PubMedID- 22282247 | renal impairment in multiple myeloma: presenting features in different departments. |
| PubMedID- 21778706 | A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence. |
| PubMedID- 23364621 | Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. |
| PubMedID- 25246256 | Clinical characteristics of multiple myeloma with renal impairment and the efficacy of different treatments. |
| PubMedID- 26117025 | Clinical research about risk factors and reversible predictors in renal impairment due to multiple myeloma. |
| PubMedID- 22541094 | Relationship between the catalysis of bence jones protein and renal impairment in patients with multiple myeloma. |
| PubMedID- 23384902 | Exploration of early assessment of renal impairment in multiple myeloma. |
| PubMedID- 25083819 | Reversal of renal dysfunction significantly affects the prognosis of multiple myeloma (mm) with renal impairment (ri). |
| PubMedID- 23996482 | We conclude that a bortezomib-containing treatment before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in patients with newly diagnosed multiple myeloma. |
| PubMedID- 24064839 | renal impairment in multiple myeloma and related disorders. |
| PubMedID- 21951682 | Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (vmpt-vt) versus bortezomib-melphalan-prednisone (vmp) in untreated multiple myeloma patients with renal impairment. |
| PubMedID- 22237937 | Cyclophosphamide-containing regimen (tcd) is superior to melphalan-containing regimen (mpt) in elderly multiple myeloma patients with renal impairment. |
| PubMedID- 22739205 | Catalytic activity of bence jones proteins in renal impairment of patients with multiple myeloma - review. |
| PubMedID- 22022183 | However, some reports show that hsct may reverse renal impairment in patients with multiple myeloma and the prognosis of patients with hsct is not different from that of patients without renal involvement (4, 13). |
| PubMedID- 19930441 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of italian myeloma network gimema. |
| PubMedID- 20956629 | renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. |
Page: 1